WO2002072525A1 - Procede de production d'un derive d'acide bicyclocarboxylique - Google Patents
Procede de production d'un derive d'acide bicyclocarboxylique Download PDFInfo
- Publication number
- WO2002072525A1 WO2002072525A1 PCT/JP2002/002254 JP0202254W WO02072525A1 WO 2002072525 A1 WO2002072525 A1 WO 2002072525A1 JP 0202254 W JP0202254 W JP 0202254W WO 02072525 A1 WO02072525 A1 WO 02072525A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid derivative
- producing
- alkyl
- oxobicyclo
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 7
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims abstract description 4
- JBPOZANHTUTRKU-UHFFFAOYSA-N 2-oxobicyclo[3.1.0]hex-3-ene-6-carboxylic acid Chemical class C1=CC(=O)C2C(C(=O)O)C21 JBPOZANHTUTRKU-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 28
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- DIWVNJFXRKZAGI-UHFFFAOYSA-N 2-amino-3-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid Chemical class C1C(F)C(N)(C(O)=O)C2C(C(O)=O)C12 DIWVNJFXRKZAGI-UHFFFAOYSA-N 0.000 abstract description 2
- OEBJBBSPVBRJFD-UHFFFAOYSA-N 4-hydroxy-2-oxobicyclo[3.1.0]hexane-6-carboxylic acid Chemical class OC1CC(=O)C2C(C(O)=O)C12 OEBJBBSPVBRJFD-UHFFFAOYSA-N 0.000 abstract description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- -1 isobutoxyethyl group Chemical group 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000018899 Glutamate Receptors Human genes 0.000 description 4
- 108010027915 Glutamate Receptors Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000029033 Spinal Cord disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 208000021245 head disease Diseases 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- AJHWHPPPSQWXRX-UHFFFAOYSA-N 2-fluoro-6-phenylaniline Chemical group NC1=C(F)C=CC=C1C1=CC=CC=C1 AJHWHPPPSQWXRX-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- FDUCTWUYWGBRQB-UHFFFAOYSA-N N-bis(dipentylamino)phosphoryl-N-pentylpentan-1-amine Chemical compound C(CCCC)N(P(=O)(N(CCCCC)CCCCC)N(CCCCC)CCCCC)CCCCC FDUCTWUYWGBRQB-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 1
- UITYZVKVKPVDPH-UHFFFAOYSA-N [I].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound [I].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UITYZVKVKPVDPH-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000005427 anthranyl group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- UZJBOHHDWXQTEF-UHFFFAOYSA-N pocl3 pyridine Chemical compound ClP(Cl)(Cl)=O.C1=CC=NC=C1 UZJBOHHDWXQTEF-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- YOXCYXPIIFUVDQ-UHFFFAOYSA-N pyridine;thionyl dichloride Chemical compound ClS(Cl)=O.C1=CC=NC=C1 YOXCYXPIIFUVDQ-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 150000003958 selenols Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
- C07C67/327—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by elimination of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a method for producing a 2-oxobicyclo [3.1.0] hex-3-ene-16-carboxylic acid derivative.
- Metapotropic glutamate receptors a type of glutamate receptor, are classified pharmacologically into three groups. Among them, group 2 (mG 1 uR 2X mG 1 uR3) binds to 7-denyl cyclase and suppresses forskolin-stimulated accumulation of cyclic adenosine monophosphate (cAMP) (Trends Pharmacol. Sci. , 14 13 (1993)). Therefore, compounds that act on the group 2 metapotropic glutamate receptor are psychiatric disorders such as schizophrenia, anxiety and related disorders, depression, bipolar disorder, and epilepsy.
- group 2 mG 1 uR 2X mG 1 uR3
- cAMP cyclic adenosine monophosphate
- An object of the present invention is to provide psychiatric disorders such as schizophrenia, anxiety and related disorders, depression, bipolar disorder, epilepsy, etc., as well as drug dependence, cognitive disorders, Alzheimer's disease, Huntington's disease, Group 2 metatropic dalminic acid receptor with therapeutic and preventive effects on neurological diseases such as Parkinson's disease, dyskinesias associated with muscle stiffness, cerebral ischemia, cerebral insufficiency, spinal cord disorders, and head disorders 2_Amino-3-fluoropropyl acting [3.1.0] Hexane Intermediate useful for efficient synthesis of 1,6-dicarboxylic acid 2,6-oxobicyclo [3.1.0] hex-1-ene _ An object of the present invention is to provide a method for producing a 6-carboxylic acid derivative (2). Disclosure of the invention
- R 1 represents a hydrogen atom, d-6 alkyl group, C 3 _6 cycloalkyl group, C 3 - 6 cycloalkyl C i - 6 alkyl group, substituted with a substituted or unsubstituted phenyl group the C i - 6 alkyl group, a C 6 alkoxy C 6 alkyl groups, C physician 6 hydroxyalkyl group, C 6 alkylthio C 6 alkyl groups, C WINCH 6 mercaptoalkyl group or a substituted or unsubstituted phenylene Le group, R 2 Represents a protecting group for a hydrogen atom or a hydroxyl group.
- Formula (2) 1 The reaction of a 4-hydroxy-2-oxobicyclo [3.1.0] hexane-6-carbox
- Cn-m indicates that the group that follows has n to m carbon atoms.
- the d-6 alkyl group refers to a linear or branched alkyl group, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a t-butyl group, a pentyl group, an isopentyl group, Examples include 1-ethylpropyl group, hexyl group, isohexyl group, 2-ethylbutyl group, heptyl group, isopentyl group, hexyl group, and isohexyl group.
- the cycloalkyl groups such as cyclopropyl group, a cycloalkyl Butyl, cyclopentyl, cyclohexyl and the like.
- the C 3-6 cycloalkyl Ci- 6 alkyl group includes, for example, a cyclopropylmethyl group, a cyclobutylmethyl group, a cyclopentylmethyl group, a cyclohexylmethyl group and the like.
- a substituted or unsubstituted phenyl group is a halogen atom such as a hydrogen atom, a fluorine atom, a chlorine atom, or a bromine atom, a Ci- 6 alkyl group, a d-6 alkanoyl group, a cyano group, a nitro group, a hydroxy group, Arbitrary groups selected from d-6 alkoxy groups such as methoxy groups
- the Ci- 6 alkyl group substituted with a substituted or unsubstituted phenyl group refers to a linear or branched alkyl group substituted with one or two phenyl groups, such as benzyl group, diphenyl group Examples include a methyl group, a 1-phenylethyl group, a 2-phenylethyl group, and a 4-methoxybenzyl group.
- the d-6 alkoxy d-6 alkyl group represents a linear or branched alkoxyalkyl group, eg if a methoxymethyl group, ethoxymethyl group, Metokishechiru group, Etokishechiru group, Puropokishechiru group, Isopuropokishe A tyl group, a butoxystyl group, an isobutoxyethyl group, a pentyloxyl group, an isopentyloxethyl group and the like.
- Examples of the d- 6 hydroxyalkyl group include a 2-hydroxyethyl group, a 3-hydroxypropyl group, and a 2,3-dihydroxypropyl group.
- the d- 6 alkanoyl group refers to a linear or branched alkanoyl group, for example, a formyl group, an acetyl group, a pivaloyl group and the like.
- the C 6 alkylthio d- 6 alkyl group represents a linear or branched alkylthioalkyl group, such as a methylthiomethyl group and a 2-methylthioethyl group.
- Examples of the d- 6 mercaptoalkyl group include a 2-mercaptoethyl group, a 3-mercaptopropyl group, and a 2,3-dimercaptopropyl group.
- At least one hydrogen atom on the group is, for example, a fluorine atom, a chlorine atom, a bromine atom, a halogen atom such as an iodine atom, a nitro group, an amino group, a hydroxyl group, a thiol group, and formyl.
- a non-hydrogen atom such as a group
- a non-hydrogen atom such as a group
- the number of carbon atoms in these substituents is not included in n or m described above.
- the hydroxyl-protected form refers to a form protected by a general hydroxyl-protected group, for example, a silyloxy form such as a trimethylsilyloxy group or a t-butyldimethylsilyloxy group, or an acetoxy group or a trifluoroacetoxy group. It shows an acylated compound such as a group.
- the compound represented by the formula (1) has four asymmetric carbon atoms, and the compound represented by the formula (2) has three asymmetric carbon atoms. Therefore, the compound of the present invention can exist as an optically active compound, a mixture of enantiomers such as enantiomers and racemates, and a mixture of diastereomers. That is, the compounds of the present invention include all optically active compounds of the compounds represented by the formulas (1) and (2), enantiomeric mixtures thereof, such as enantiomers and racemates, and diastereomeric mixtures.
- the compound of the formula (2) in the present invention can be produced by the following reaction.
- R 1 and R 2 are as defined above, and X 1 is a chlorine atom, a bromine atom, an iodine atom, a trifluoromethanesulfonyloxy group, a methanesulfonyloxy group, a p-toluenesulfonyloxy group. It indicates sulfonyl Ruokishi groups such as, X 2 has the formula
- R 3 S (0) ⁇ — or R 3 Se ( ⁇ ) n — (wherein, R 3 represents a methyl group, an ethyl group and a phenyl group, and n represents an integer of 0 to 2).
- R 3 represents a methyl group, an ethyl group and a phenyl group, and n represents an integer of 0 to 2).
- Group. The protection and deprotection of general hydroxyl groups used in the reaction is described in detail in PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, THEODORA W. GREENE and PETER GM WUTS. Incorporated in the specification.
- Hydrocarbon solvents for example, halogen solvents, such as dichloromethane and chloroform, alcohols, for example, methanol, ethanol, isopropyl alcohol, etc., for example, ethers, for example, tetrahydrofuran, getyl ether, 1,2-dimethoxetane, etc.
- the compound (2) can be obtained by reacting in an amide such as N, N-dimethylformamide or N-methylpyrro-udone, acetonitrile, dimethylsulfoxide, hexamethylphosphoramide, or a mixed solvent thereof.
- the base refers to amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo [5.4.0] -7-pandacene, for example, potassium carbonate, sodium carbonate, hydrogen carbonate and the like.
- Inorganic bases such as sodium, for example, metal alcoholates such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
- Acids include, for example, inorganic acids such as hydrogen chloride, hydrogen bromide, sulfuric acid, etc.
- Organic acids such as toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, and acetic acid.
- the compound (1) in which R 2 is a hydrogen atom can be dehydrated under the conditions of, for example, phosphoryl chloride-pyridine, thionyl chloride-pyridine or the like to give the compound (2).
- the compound (1) in which R 2 is a hydrogen atom is converted to a hydrocarbon-based solvent such as benzene, toluene, hexane, etc., a halogen-based solvent such as dichloromethane, chloroform, dimethyl ether, 1,2-dimethoxyethane or the like.
- a hydrocarbon-based solvent such as benzene, toluene, hexane, etc.
- a halogen-based solvent such as dichloromethane, chloroform, dimethyl ether, 1,2-dimethoxyethane or the like.
- Tongue Monoters for example, amides such as N, N-dimethylformamide and N-methylpyrrolidone, acetonitrile, or an inert solvent such as a mixed solvent thereof, for example, triethylamine, disopropylethylamine, pyridine, In the presence or absence of a base such as an amine such as 4-dimethylaminopyridine or an inorganic base such as potassium carbonate or sodium hydrogencarbonate, for example, trifluoromethanesulfonic anhydride, N-phenylbis (trifluoromethanesulfonic) Imide), methanesulfonyl chloride, p-toluenesulfonyl chloride or other sulfonylating reagents, or, for example, thionyl chloride, oxalyl chloride, triphenylphosphine monotetrabromide, N-bromosuccinate imidotriphenylphosphine
- the compound (10) is reacted with a thiol such as benzenethiol or methanethiol, for example, a selenol such as benzenesenol in the presence of a base such as sodium hydride, potassium carbonate or triethylamine. Reacts in the presence of a base in an inert solvent, or oxidizes with an oxidizing agent such as m-chloroperbenzoic acid, hydrogen peroxide, etc.
- the compound (2) can be obtained by reacting in a solvent in the presence or absence of a base.
- the inert solvent means a hydrocarbon solvent such as benzene, toluene and hexane; a halogen solvent such as dichloromethane and chloroform; alcohols such as methanol, ethanol and isopropyl alcohol;
- ethers such as tetrahydrofuran, dimethyl ether, 1,2-dimethoxyethane, and the like, for example, N, N-dimethylformamide, N-methyl
- An amide such as tylpyrrolidone, acetonitrile, dimethylsulfoxide, hexamylphosphoramide, or a mixed solvent thereof is shown.
- a base is, for example, triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo [ 5 • 4.0] —Amines such as 7-indene and the like; inorganic bases such as potassium carbonate, sodium carbonate and sodium hydrogencarbonate; and metal alcoholates such as sodium methoxide, sodium ethoxide and potassium t-butoxide Is shown.
- each diastereomer can be separated by, for example, column chromatography using ordinary silica gel or a recrystallization method.
- each of the (+) and (1) optically active compounds is obtained by the HPLC method using a chiral carrier such as a cellulose rubamate derivative or an amylose carbamate derivative. Optical splitting can be performed. Further, after the conversion and the R 1 of general ester moiety hydrolyzable to (PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, THEODORA .
- GREENE and PETER GM WUTS serial mounting methods Author) by hydrogen atoms, for example (+) or (I) 1-11 phenyleluamine, (+) or (1) -phenyldaricinol, (+) or (1) _2-amino-1 butylamine, (+) or (1) -araninol, brucine, cinchonidine, (+) And (1) regardless of whether it is converted to a salt with an optically active amine such as cinchonine, quinine, quinidine, dehydroabiethylamine, or an amide derivative with an optically active primary or secondary amine. Can be optically divided into each optically active substance.
- the reaction mixture was poured into a saturated aqueous solution of sodium hydrogen carbonate and ice, and extracted three times with chloroform and twice with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, the desiccant was filtered off, and the filtrate was concentrated under reduced pressure. 0.72 g of the obtained residue and 66 mg of p-toluenesulfonic acid monohydrate were diluted with 6 mL of benzene, and the mixture was heated under reflux for 1.5 hours. 66 mg of p-toluenesulfonic acid monohydrate was added, and the mixture was further heated under reflux for 1 hour.
- 2-oxobicyclo [3.1.0] hex-3-ene-6-potassium sulfonic acid derivative (2) Psychiatric disorders such as depression, bipolar disorder and epilepsy, such as drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, motor dysfunction associated with muscle stiffness, cerebral ischemia, cerebral insufficiency, and spinal cord Group 2 has therapeutic and prophylactic effects on neurological diseases such as disability and head injury. 2 Acts on metapotropic glutamate receptor. It is useful as an intermediate for the synthesis of the dicarponic acid derivative (3).)
- the 2-amino-3-fluorobicyclo [3.1.0] hexane-2,6- Dicarboxylic acid derivative (3 ) Can be manufactured efficiently.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02702875A EP1369408A4 (en) | 2001-03-14 | 2002-03-11 | PROCESS FOR PREPARING BICYCLOCARBOXYLIC ACID DERIVATIVES |
US10/471,537 US20040082806A1 (en) | 2001-03-14 | 2002-03-11 | Process for producing bicyclocarboxylic acid derivative |
KR10-2003-7011887A KR20030083732A (ko) | 2001-03-14 | 2002-03-11 | 비시클로카르복실산 유도체의 제조 방법 |
CA002441127A CA2441127A1 (en) | 2001-03-14 | 2002-03-11 | Process for producing bicyclocarboxylic acid derivative |
JP2002571442A JP4124656B2 (ja) | 2001-03-14 | 2002-03-11 | ビシクロカルボン酸誘導体の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-71743 | 2001-03-14 | ||
JP2001071743 | 2001-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002072525A1 true WO2002072525A1 (fr) | 2002-09-19 |
Family
ID=18929428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/002254 WO2002072525A1 (fr) | 2001-03-14 | 2002-03-11 | Procede de production d'un derive d'acide bicyclocarboxylique |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040082806A1 (ja) |
EP (1) | EP1369408A4 (ja) |
JP (1) | JP4124656B2 (ja) |
KR (1) | KR20030083732A (ja) |
CN (1) | CN1498201A (ja) |
CA (1) | CA2441127A1 (ja) |
WO (1) | WO2002072525A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1689727A2 (en) * | 2003-11-07 | 2006-08-16 | Taisho Pharmaceutical Co., Ltd | Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto |
JP2008100951A (ja) * | 2006-10-19 | 2008-05-01 | Kawaguchi Yakuhin Kk | 2−シクロペンタデセノンの製造方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108383719B (zh) * | 2018-05-05 | 2020-09-15 | 湖北荆洪生物科技股份有限公司 | 一种环己甲酸的生产工艺 |
CN108675925B (zh) * | 2018-05-05 | 2020-09-15 | 湖北荆洪生物科技股份有限公司 | 一种环戊甲酸的生产工艺 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000029371A1 (en) * | 1998-11-13 | 2000-05-25 | Eli Lilly And Company | Excitatory amino acid receptor modulators |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1052246T3 (da) * | 1998-01-28 | 2003-06-16 | Taisho Pharmaceutical Co Ltd | Fluorholdige aminosyrederivater |
EP1164121B1 (en) * | 1999-03-25 | 2008-10-29 | Taisho Pharmaceutical Co., Ltd | Novel carboxylic acid derivatives and process for producing the same |
-
2002
- 2002-03-11 JP JP2002571442A patent/JP4124656B2/ja not_active Expired - Fee Related
- 2002-03-11 WO PCT/JP2002/002254 patent/WO2002072525A1/ja not_active Application Discontinuation
- 2002-03-11 EP EP02702875A patent/EP1369408A4/en not_active Withdrawn
- 2002-03-11 CN CNA028063260A patent/CN1498201A/zh active Pending
- 2002-03-11 KR KR10-2003-7011887A patent/KR20030083732A/ko not_active Application Discontinuation
- 2002-03-11 US US10/471,537 patent/US20040082806A1/en not_active Abandoned
- 2002-03-11 CA CA002441127A patent/CA2441127A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000029371A1 (en) * | 1998-11-13 | 2000-05-25 | Eli Lilly And Company | Excitatory amino acid receptor modulators |
Non-Patent Citations (2)
Title |
---|
DOMINGUEZ C. ET AL.: "Asymmetric synthesis of (+)-2-aminobicyclo(3.1.0)hexane-2,6-dicarboxylic acid", TETRAHEDRON: ASYMMETRY, vol. 8, no. 4, 1997, pages 511 - 514, XP004054387 * |
See also references of EP1369408A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1689727A2 (en) * | 2003-11-07 | 2006-08-16 | Taisho Pharmaceutical Co., Ltd | Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto |
JP2007513070A (ja) * | 2003-11-07 | 2007-05-24 | 大正製薬株式会社 | ビシクロ[3.1.0]ヘキサン誘導体およびその中間体の製造方法関連出願に対する相互参照本出願は、2003年11月7日に出願された米国仮出願第60/518,391号の合衆国法典第35巻(35U.S.C.)第119条(e)に基づく優先権を主張する。 |
EP1689727A4 (en) * | 2003-11-07 | 2008-12-31 | Taisho Pharmaceutical Co Ltd | PROCESS FOR PREPARING BICYCLO [3.1.0] HEXENE DERIVATIVES AND INTERMEDIATES THEREFOR |
US7786314B2 (en) | 2003-11-07 | 2010-08-31 | Taisho Pharmaceutical Co., Ltd | Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto |
JP4742239B2 (ja) * | 2003-11-07 | 2011-08-10 | 大正製薬株式会社 | ビシクロ[3.1.0]ヘキサン誘導体およびその中間体の製造方法 |
JP2008100951A (ja) * | 2006-10-19 | 2008-05-01 | Kawaguchi Yakuhin Kk | 2−シクロペンタデセノンの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4124656B2 (ja) | 2008-07-23 |
CN1498201A (zh) | 2004-05-19 |
EP1369408A1 (en) | 2003-12-10 |
CA2441127A1 (en) | 2002-09-19 |
US20040082806A1 (en) | 2004-04-29 |
EP1369408A4 (en) | 2005-12-28 |
KR20030083732A (ko) | 2003-10-30 |
JPWO2002072525A1 (ja) | 2004-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU577622B2 (en) | Preparation of (threo)-1-aryl-2-acylamido-3-fluro-1-propanols | |
AU734812B2 (en) | Fluorine-containing amino acid derivatives | |
WO2002000605A1 (fr) | Nouveaux derives d'acide dicarboxylique | |
TW201500330A (zh) | 環己烯酮組成物及其製造方法 | |
CZ20023665A3 (cs) | Zkrácená syntéza derivátů 3,3-diarylpropylaminu | |
WO2002072525A1 (fr) | Procede de production d'un derive d'acide bicyclocarboxylique | |
JP2022501386A (ja) | ピラゾール化合物を製造する方法 | |
KR100699393B1 (ko) | 중간체 및 이를 사용한 불소 함유 카르복실산 유도체의제조 방법 | |
JP4742239B2 (ja) | ビシクロ[3.1.0]ヘキサン誘導体およびその中間体の製造方法 | |
JP4399932B2 (ja) | 中間体及びそれを用いた含フッ素アミノ酸化合物の製造方法 | |
EP1164121B1 (en) | Novel carboxylic acid derivatives and process for producing the same | |
JP4505926B2 (ja) | 新規カルボン酸誘導体及びその製造方法 | |
WO2022114138A1 (ja) | アミノ酸誘導体の製造方法 | |
JP7134982B2 (ja) | ジアルキルジヒドロナフタレン誘導体の製造方法 | |
JP2013100279A (ja) | マンデル酸アミド誘導体の製造方法及びその中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002571442 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037011887 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2441127 Country of ref document: CA Ref document number: 2002236286 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002702875 Country of ref document: EP Ref document number: 10471537 Country of ref document: US Ref document number: 028063260 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002702875 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002702875 Country of ref document: EP |